Watching a Prostate Cancer Isn’t Giving Up: Why the Best Treatment Is Sometimes a Schedule

Two older men seen from behind walking a gravel coastal trail at a pewter-grey dawn, sea grass bending in the wind, illustrating active surveillance for prostate cancer.
  • In the ProtecT trial, 1,643 men with localized prostate cancer found by PSA testing were randomly assigned to active monitoring, surgery or radiation; after a median of 15 years, death from prostate cancer was low and not significantly different among the groups: 3.1%, 2.2% and 2.9%.
  • Among more than 14,000 fully examined prostates removed at four large academic centers, not a single cancer with a Gleason score of 6 or lower, now called Grade Group 1, had spread to the lymph nodes once the slides were graded by current standards.
  • In the PRECISION trial, men who had an MRI first, with a biopsy aimed only at suspicious areas, were more often diagnosed with clinically significant cancer (38% vs 26%) and less often with insignificant cancer, and 28% avoided a biopsy altogether.

It is Movember, so let’s talk about the sentence every man dreads: “The biopsy shows cancer.” Most men hear that and want it out, immediately. Here is the part almost nobody says out loud. For many men with a newly found, low-grade prostate cancer, the best treatment is a schedule, not surgery. That schedule is called active surveillance for prostate cancer: regular PSA blood tests, MRI scans and repeat biopsies, with treatment started only if the cancer shows signs of changing. It can sound like doing nothing, or like a doctor shrugging. It is neither. Prostate cancer is not one disease. The lowest grade, Grade Group 1 (what used to be called Gleason 6), behaves so gently that many experts question whether it should be called cancer at all, while higher grades can be dangerous and deserve real treatment. The fear is understandable. The question is whether removing or radiating a slow, low-grade tumor actually helps you live longer, or mainly changes how you live.

The strongest answer comes from the ProtecT trial in the United Kingdom. It randomly assigned 1,643 men with PSA-detected localized prostate cancer to monitoring, surgery or radiation and followed them for a median of 15 years. Death from prostate cancer was low in every group, 3.1%, 2.2% and 2.9%, with no significant difference, and overall survival was similar. The honest catch: men in the monitoring group were about twice as likely to see their cancer spread, 9.4% versus roughly 5%, and that trial’s monitoring was mostly PSA tests, cruder than today’s MRI-guided surveillance. More than a third of those men also had intermediate- or high-risk disease, not just low grade. Meanwhile, surgery left the biggest lasting hit to urinary control and sexual function. In a Canadian surveillance group of 993 men, 15-year survival from prostate cancer was 94.3%, and more than half had never needed treatment. Now the surprising detail. In more than 14,000 removed prostates, no Grade Group 1 tumor had spread to lymph nodes. Every case first labeled low grade that had spread turned out, on second review, to contain higher-grade cancer.

Is active surveillance for prostate cancer safe?

For low-risk disease, it is the option the major American guidelines call preferred, if it is done properly. I would never rush a man with low-grade disease into surgery without first talking about active surveillance. What I care about is getting the diagnosis right, because that lymph-node study tells you the real risk is a higher-grade cancer that was missed or under-called. That is why MRI matters. In the PRECISION trial, men who had an MRI first, with biopsies aimed at what the scan flagged, were diagnosed with significant cancer more often, 38% versus 26%, picked up fewer harmless cancers, and 28% skipped a biopsy entirely. If you are told you have Grade Group 1 prostate cancer, here is what I would ask: Have I had a good-quality prostate MRI? Has an experienced pathologist reviewed the biopsy? Is my cancer truly low risk, with a PSA under 10 and a small tumor, not just a low grade? What is my surveillance schedule, and what change would make us treat? And surveillance means showing up; the men it protects are the ones who keep their appointments. If your cancer is Grade Group 2 or higher, the conversation is different and treatment deserves serious discussion. Watching closely is not giving up. It is refusing to trade your quality of life for a cancer that was never going to kill you.

References

  1. Hamdy, F. C., Donovan, J. L., Lane, J. A., Metcalfe, C., Davis, M., Turner, E. L., et al. (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 388(17), 1547-1558.
  2. Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., et al. (2016). Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 375(15), 1425-1437.
  3. Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., et al. (2015). Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Journal of Clinical Oncology, 33(3), 272-277.
  4. Ross, H. M., Kryvenko, O. N., Cowan, J. E., Simko, J. P., Wheeler, T. M., & Epstein, J. I. (2012). Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? American Journal of Surgical Pathology, 36(9), 1346-1352.
  5. Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., et al. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767-1777.
  6. Eastham, J. A., Auffenberg, G. B., Barocas, D. A., Chou, R., Crispino, T., Davis, J. W., et al. (2022). Clinically localized prostate cancer: AUA/ASTRO guideline, part I: Introduction, risk assessment, staging, and risk-based management. Journal of Urology, 208(1), 10-18.

Comments are closed

Christopher L. Bray, MD, PhD, CPE, FACP — board-certified in Internal and Integrative Medicine.

Archangel Michael Health is a telehealth-first Direct Primary Care practice founded by Christopher L. Bray, MD, PhD, CPE, FACP, based in Gainesville, Florida, serving patients by telehealth in Florida, Georgia, Texas, Arizona, North Carolina, Tennessee, and New Hampshire, with house calls in Alachua County, Florida.

Learn more about becoming a patient: https://archangelmichaelhealth.com/inquiries/

Latest Comments

No comments to show.